KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Short-term Investments: 2011-2024

Historic Short-term Investments for Pacira BioSciences (PCRX) over the last 14 years, with Dec 2024 value amounting to $207.8 million.

  • Pacira BioSciences' Short-term Investments fell 52.49% to $98.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.7 million, marking a year-over-year decrease of 52.49%. This contributed to the annual value of $207.8 million for FY2024, which is 65.90% up from last year.
  • Latest data reveals that Pacira BioSciences reported Short-term Investments of $207.8 million as of FY2024, which was up 65.90% from $125.3 million recorded in FY2023.
  • Pacira BioSciences' Short-term Investments' 5-year high stood at $421.7 million during FY2020, with a 5-year trough of $70.8 million in FY2021.
  • Moreover, its 3-year median value for Short-term Investments was $184.5 million (2022), whereas its average is $172.5 million.
  • In the last 5 years, Pacira BioSciences' Short-term Investments slumped by 83.20% in 2021 and then soared by 160.50% in 2022.
  • Pacira BioSciences' Short-term Investments (Yearly) stood at $421.7 million in 2020, then plummeted by 83.20% to $70.8 million in 2021, then surged by 160.50% to $184.5 million in 2022, then plummeted by 32.10% to $125.3 million in 2023, then skyrocketed by 65.90% to $207.8 million in 2024.